Last updated on July 2018

A 4-Week Study of the Safety Efficacy and Pharmacokinetics of JZP-110 [(R)-2-amino-3-phenylpropylcarbamate Hydrochloride] in Subjects With Parkinson's Disease and Excessive Sleepiness

Brief description of study

This study is a 4-week, multicenter, randomized, double-blind, placebo-controlled, ascending dose, 4-period crossover study designed to evaluate the safety, tolerability, efficacy, and PK of JZP-110 (75, 150, and 300 mg) in the treatment of excessive sleepiness in adult subjects with idiopathic PD.

Clinical Study Identifier: NCT03037203

Contact Investigators or Research Sites near you

Start Over

Richard Bogan

SleepMed of South Carolina
Columbia, SC United States